You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study

 

Online download statistics by month:

Online download statistics by month: January 2022 to September 2025

AbstractFullPdf
Jan 2022319330127
Feb 202214714853
Mar 202212512653
Apr 202213013362
May 202210510640
Jun 202211211534
Jul 202212012036
Aug 202212312427
Sep 202211011075
Oct 202216116780
Nov 202218318356
Dec 202220620530
Jan 20231591599
Feb 202312212248
Mar 202311511534
Apr 202312212224
May 202312412330
Jun 202319019031
Jul 202314714724
Aug 202316016020
Sep 202311611617
Oct 202310110123
Nov 202314514524
Dec 202319219335
Jan 202414514728
Feb 202414414422
Mar 20249899103
Apr 2024313134
May 2024353622
Jun 2024454429
Jul 2024989833
Aug 202411811842
Sep 2024586261
Oct 2024565647
Nov 2024656849
Dec 2024838446
Jan 2025515426
Feb 202510410419
Mar 2025656532
Apr 202514614642
May 2025808048
Jun 2025293019
Jul 2025110
Sep 2025110
Total498750281694